MaaT Pharma
Created in 2014
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
556 1,413 15,440Activities
Technologies
Entity types
Location
70 Av. Tony Garnier, 69007 Lyon, France
Lyon
France
Employees
Scale: 51-200
Estimated: 86
SIREN
808370100Engaged catalyst
38
0 0Added in Motherbase
5 years, 6 months ago
Value proposition
Boosting Survival Through Innovative Immune Modulation
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Microbiome, Microbiota, Microbiology, pharma, GvHD, Leukemia, Dysbiosis, Symbiosis, Biotech, oncology, cancer, gut microbiota, allo-HSCT, Gut microbiome, Immune modulation, and Blood cancersOriginal language
Boosting Survival Through Innovative Immune Modulation
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
Hervé Affagard, CEO & Co-founder
MaaT Pharma - Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
https://www.maatpharma.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Ministère chargé de l'Enseignement supérieur et de la Recherche Government Administration | Ministère chargé de l'Enseignement supérieur et de la Recherche Government Administration | Other 11 Apr 2025 | | |
 Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 13 Apr 2025 | | |
 WAOUP Business Consulting and Services | WAOUP Business Consulting and Services | Other 31 Jan 2025 | | |
 Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Other 17 Jun 2024 | | |
 | Biotechnology Innovation Organization | Other 22 May 2024 | | |
 | Ministère de la Santé | Other 11 Apr 2024 | | |
 Direction Générale des Entreprises National and local authorities, Government Administration | Direction Générale des Entreprises National and local authorities, Government Administration | Other 11 Apr 2025 | | |
 France Travail Human ressources, Government Administration | France Travail Human ressources, Government Administration | Other 21 Dec 2023 | | |
 | Gouvernement | Other 11 Apr 2025 | | |
 BNP Paribas Bank, Banking | BNP Paribas Bank, Banking | Other 21 Oct 2023 | | |